HK$100.50
2.60% yesterday
Hong Kong, Oct 06, 10:08 am CET
ISIN
KYG4818G1010
Symbol
1801

Innovent Biologics Stock price

HK$100.50
+0.00 0.00% 1M
+60.85 153.47% 6M
+63.90 174.59% YTD
+50.70 101.81% 1Y
+75.30 298.81% 3Y
+39.95 65.98% 5Y
+83.92 506.15% 10Y
+83.92 506.15% 20Y
Hong Kong, Closing price Mon, Oct 06 2025
+2.55 2.60%
ISIN
KYG4818G1010
Symbol
1801
Industry

Key metrics

Basic
Market capitalization
HK$172.5b
Enterprise Value
HK$165.7b
Net debt
positive
Cash
HK$10.4b
Shares outstanding
1.7b
Valuation (TTM | estimate)
P/E
132.4 | 184.4
P/S
13.8 | 12.7
EV/Sales
13.3 | 12.2
EV/FCF
-
P/B
10.9
Financial Health
Equity Ratio
60.7%
Return on Equity
-0.7%
ROCE
7.4%
ROIC
12.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
HK$12.5b | HK$13.6b
EBITDA
- | HK$1.4b
EBIT
HK$1.5b | HK$825.3m
Net Income
HK$1.2b | HK$878.4m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
53.2% | 31.7%
EBITDA
- | 249.2%
EBIT
224.4% | 1,701.3%
Net Income
188.4% | 949.4%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
85.4%
EBITDA
- | 10.5%
EBIT
12.0%
Net
9.9% | 6.5%
Free Cash Flow
-
More
EPS
HK$0.7
FCF per Share
-
Short interest
-
Employees
6k
Rev per Employee
HK$1.8m
Show more

Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Innovent Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Innovent Biologics forecast:

31x Buy
89%
4x Hold
11%

Analyst Opinions

35 Analysts have issued a Innovent Biologics forecast:

Buy
89%
Hold
11%

Financial data from Innovent Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
12,487 12,487
53% 53%
100%
- Direct Costs 1,821 1,821
27% 27%
15%
10,666 10,666
59% 59%
85%
- Selling and Administrative Expenses 6,234 6,234
32% 32%
50%
- Research and Development Expense 2,504 2,504
15% 15%
20%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,494 1,494
224% 224%
12%
Net Profit 1,238 1,238
188% 188%
10%

In millions HKD.

Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.

Head office China
Employees 5,659
Website www.innoventbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today